Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Inclusion Criteria: * Pathological diagnosis of extranodal natural killer/T-cell lymphoma, nasal type. * stage IV disease and resistant to L-asparaginase-based combined chemotherapy.(Definition of L-asparaginase resistance: Progression during treatment or no response to treatment). * Eastern Cooperative Oncology Group (ECOG ) performance status 0\~3. * Preserved organ functions for: absolute neutrophil counter (ANC)\>1.0×109/L, Platelet\>50×109/L, hemoglobin\>80g/L, total bilirubin (TBIL)\<2×ULN, alanine transaminase (ALT)\<2×ULN, normal serum creatinine，fibrinogen≥1.0g/L, LVEF≥50%. * Signed Informed consented. Exclusion Criteria: * patients with a disease resistant to L-asparaginase but may benefit from a radiotherapy. * HIV, hepatitis virus C (HCV), or active hepatitis virus B (HBV) infection with HBV DNA≥105 copies/ml. * Significant complications: autoimmune disease, severe infection, or liver cirrhosis, hemophagocytic lymphohistiocytosis, disseminated intravascular coagulation, uncontrolled hypertension or diabetes, hemorrhagic or thrombotic events within 6 months. * Mental disorders. * Pregnant or lactation * Peptic ulcer * Enrolled in other trial treatment